Autopsy report · NCT03657095

A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension

“The pivotal study, BPS-314d-MR-PAH-302 (NCT01908699), failed to demonstrate efficacy.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 7 months before it started.
• Ran for about 7 months before it stopped.
• 112 participants enrolled.
• Results were posted on the registry 1 year 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Lung Biotechnology PBC

Sponsor type

Industry

Conditions

Pulmonary Arterial Hypertension

Interventions

Esuberaprost; Placebo

Participants

112

Sites

45

Countries

Israel, United States

Trials that died the same way

• A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral Palsy
  “Failure of TV50717-CNS-30080 (parent study) to meet the primary efficacy endpoint” (66% match in meaning)
• Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)
  “The study was terminated based on review of Phase 2 efficacy data” (62% match in meaning)
• Phase IIB Pilot of Atazanavir + Raltegravir
  “Efficacy endpoint met, but overall experimental dosing regimen not considered optimal to support further clinical development in this population.” (60% match in meaning)
• Utility of Tocolytic Therapy for Maintenance Tocolysis in the Management of Threatened Preterm Delivery
  “have been published new studies that it showed the ineffectiveness of the treatments proposed in this study.” (60% match in meaning)
• Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label)
  “The study treatment failed to demonstrate efficacy in target population in two other clinical studies (CAFQ056B2214 and CAFQ056A2212).” (60% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.